SEC Form 4 · accession 0001127602-18-004915
LABCORP HOLDINGS INC. · LH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D Ratliff
Officer — CEO, Covance Drug Development
Period of report
Feb 7, 2018
Accepted (ET)
Feb 9, 2018 · 4:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 7, 2018 | M | 1,863 | — | A | 5,990 | D | |
| Common Stock | Feb 7, 2018 | F | 560 | $169.66 | D | 5,430 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF4,F1,F3 | — | Feb 7, 2018 | M | 1,863 | D | — | — | Common Stock | 1,863 | 15,927 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- F2Stock withholding to satisfy tax withholding obligations.
- F3The Restricted Stock Units vest in three equal annual installments beginning on 2/7/18.
- F4This number reflects the aggregate number of Restricted Stock Units held by the reporting person.